<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>pASSPORT RECOMMENDATIONS, RISK FACTORS AND CARE PLAN</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:0cm;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Tw Cen MT",sans-serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Intestazione Carattere";
	margin:0cm;
	font-size:11.0pt;
	font-family:"Tw Cen MT",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Piè di pagina Carattere";
	margin:0cm;
	font-size:11.0pt;
	font-family:"Tw Cen MT",sans-serif;}
span.IntestazioneCarattere
	{mso-style-name:"Intestazione Carattere";
	mso-style-link:Intestazione;}
span.PidipaginaCarattere
	{mso-style-name:"Piè di pagina Carattere";
	mso-style-link:"Piè di pagina";}
.MsoChpDefault
	{font-family:"Tw Cen MT",sans-serif;}
.MsoPapDefault
	{margin-bottom:8.0pt;
	line-height:107%;}
 /* Page Definitions */
 @page WordSection1
	{size:841.9pt 595.3pt;
	margin:78.0pt 70.85pt 2.0cm 2.0cm;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>

</head>

<body lang=EN-US link="#6B9F25" vlink="#B26B02" style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr style='height:49.25pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:49.25pt'>
  <p class=MsoNormal>A</p>
  <p class=MsoNormal>Systen Ids - Please do not change</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:49.25pt'>
  <p class=MsoNormal>F</p>
  <p class=MsoNormal><span lang=IT>Recommendation</span></p>
  <p class=MsoNormal><span lang=IT>Title</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:49.25pt'>
  <p class=MsoNormal>G</p>
  <p class=MsoNormal>Recommendation as from PCFU (English)</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:49.25pt'>
  <p class=MsoNormal><span lang=IT>H</span></p>
  <p class=MsoNormal><span lang=IT>Care Plan PCFU</span></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:49.25pt'>
  <p class=MsoNormal>I</p>
  <p class=MsoNormal>Individualized decision (suggestion) SCP Care Plan PCFU</p>
  </td>
  <td style='height:49.25pt;border:none' width=0 height=197></td>
 </tr>
 <tr style='height:176.75pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:176.75pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T1.GUIDELINE_T1</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:176.75pt'>
  <p class=MsoNormal><span lang=IT>Subsequent thyroid cancer </span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:176.75pt'>
  <p class=MsoNormal>Counselling regarding the increased risk for developing
  differentiated thyroid  to inform their HCP if they detect a thyroid mass
  (independent of the presence or absence of associated symptoms), every 5
  years<br>
  - Physical examination of the neck as part of a complete physical
  examination, whenever a survivor is assessed by a HCP<br>
  - Counselling regarding options for differentiated thyroid carcinoma
  surveillance, at least every 5 years<br>
  If the decision to commence surveillance is made, make a shared decision for
  one of these two surveillance modalities:<br>
  - Neck palpation, every 1-2 years, starting 5 years after radiotherapy, or<br>
  - Thyroid ultrasonographyw, every 3-5 years, starting 5 years after
  radiotherapy</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:176.75pt'>
  <p class=MsoNormal>A neck palpation every 1-2 years. An ultrasound of your
  thyroid gland every 3-5 years.</p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:176.75pt'>
  <p class=MsoNormal>Neck palpation 1x/1-2 years<br>
  OR<br>
  - Thyroid ultrasound 1x/3-5 years<br>
  <br>
  Note: start surveillance 5 years after exposure</p>
  </td>
  <td style='height:176.75pt;border:none' width=0 height=707></td>
 </tr>
 <tr style='height:77.25pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:77.25pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T2.GUIDELINE_T2</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:77.25pt'>
  <p class=MsoNormal><span lang=IT>Subsequent breast cancer </span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:77.25pt'>
  <p class=MsoNormal>Mammography and breast MRI<br>
  every year if &#8805; 25 years of age or &#8805; 8 years from radiation,
  whichever occurs last </p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:77.25pt'>
  <p class=MsoNormal>A mammography and a breast MRI every year</p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:77.25pt'>
  <p class=MsoNormal>Mammography 1x/year <br>
  Breast MRI 1x year<br>
  <br>
  Note: start at age &#8805; 25 years or &#8805; 8 years from radiation,
  whichever occurs last</p>
  </td>
  <td style='height:77.25pt;border:none' width=0 height=309></td>
 </tr>
 <tr style='height:276.25pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:276.25pt'>
  <p class=MsoNormal><span lang=FR>assport_n.GUIDELINE_T3<br>
  .GUIDELINE_T3</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:276.25pt'>
  <p class=MsoNormal>Cardiac problems (High risk)</p>
  <p class=MsoNormal>Cardiomyopathy and/or</p>
  <p class=MsoNormal>Valvular disease and/or</p>
  <p class=MsoNormal>Cardiac ischemia</p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:276.25pt'>
  <p class=MsoNormal>A physical cardiac examination at every LTFU visit, at
  least every 5 years. Screening for modifiable cardiovascular risk factors
  (hypertension, diabetes, dyslipidaemia, obesity, smoking and low levels of
  physical activity).</p>
  <p class=MsoNormal>- ECG once at entry into LTFU. Repeat ECG once after the
  age of 18 years if entry into LTFU was at a younger
  age.                                                                                           
  - Echocardiogram with specific attention to left ventricular systolic
  function, to valvular structure and function and to the pericardium, starting
  2 years after treatment and at least every 2-3 years;<br>
  Echocardiogram with specific attention to left ventricular function, prior to
  pregnancy or in the first trimester, if female <br>
  - Refer to a cardiologist if an abnormal ejection fraction or if other
  abnormalities are identified<br>
  - Refer for interventions to help avert the risk of symptomatic
  cardiomyopathy if modifiable cardiovascular risk factors are identified 
  Refer to a cardiologist if an abnormal ejection fraction or if other
  abnormalities are identified<br>
  - Refer for interventions to help avert the risk of symptomatic
  cardiomyopathy if modifiable cardiovascular risk factors are identified</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:276.25pt'>
  <p class=MsoNormal>An ECG once and an echo of your heart at least every 2-3
  years [and prior to attempting pregnancy or in the first trimester]</p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:276.25pt'>
  <p class=MsoNormal>ECG 1x at entry LTFU<br>
  - Echo heart: left ventricular systolic function at least 1x/2-3 years <br>
  - Echo heart: left ventricular systolic function prior to pregnancy or in the
  first trimester (if female)<br>
  <br>
  Note: start echo 2 years after exposure. </p>
  </td>
  <td style='height:276.25pt;border:none' width=0 height=1105></td>
 </tr>
 <tr style='height:212.45pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:212.45pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T46<br>
  .GUIDELINE_T46</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:212.45pt'>
  <p class=MsoNormal>Cardiac problems (standard risk)</p>
  <p class=MsoNormal>Cardiomyopathy and/or</p>
  <p class=MsoNormal>Valvular disease and/or</p>
  <p class=MsoNormal>Cardiac ischemia</p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:212.45pt'>
  <p class=MsoNormal>A physical cardiac examination at every LTFU visit, at
  least every 5 years. Screening for modifiable cardiovascular risk factors
  (hypertension, diabetes, dyslipidaemia, obesity, smoking and low levels of
  physical activity).</p>
  <p class=MsoNormal> ECG once at entry into LTFU. Repeat ECG once after the
  age of 18 years if entry into LTFU was at a younger age.</p>
  <p class=MsoNormal>- Echocardiogram with specific attention to left
  ventricular systolic function, to valvular structure and function and to the
  pericardium, starting 2 years after treatment and at least every 5 years;<br>
  -Echocardiogram with specific attention to left ventricular function, prior
  to pregnancy or in the first trimester, if female <br>
  - Refer to a cardiologist if an abnormal ejection fraction or if other
  abnormalities are identified<br>
  - Refer for interventions to help avert the risk of symptomatic
  cardiomyopathy if modifiable cardiovascular risk factors are identified</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:212.45pt'>
  <p class=MsoNormal>An ECG once and an echo of your heart at least every 5
  years [and prior to attempting pregnancy or in the first trimester]</p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:212.45pt'>
  <p class=MsoNormal>ECG 1x at entry LTFU<br>
  - Echo heart: left ventricular systolic function + pericardium + valvular
  structure and function at least 1x/5 years <br>
  - Echo heart: left ventricular systolic function prior to pregnancy or in the
  first trimester (if female)<br>
  <br>
  Note: start echo 2 years after exposure.</p>
  </td>
  <td style='height:212.45pt;border:none' width=0 height=850></td>
 </tr>
 <tr style='height:90.7pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:90.7pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T31.GUIDELINE_T31</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:90.7pt'>
  <p class=MsoNormal><span lang=IT>Arrhythmia</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:90.7pt'>
  <p class=MsoNormal>A cardiac history at every LTFU visit, at least every 5
  years</p>
  <p class=MsoNormal> A physical cardiac examination at every LTFU visit, at
  least every 5 years <br>
  - ECG once at entry into LTFU<br>
  - Repeat ECG once after the age of 18 years if entry into LTFU was at a
  younger age</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:90.7pt'>
  <p class=MsoNormal>NO/ included in cardiac problems</p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:90.7pt'>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td style='height:90.7pt;border:none' width=0 height=363></td>
 </tr>
 <tr style='height:27.5pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:27.5pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T4<br>
  .GUIDELINE_T4</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:27.5pt'>
  <p class=MsoNormal>Male fertility problems and sexual dysfunction<br>
  Impaired fertility Impaired spermatogenesis</p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:27.5pt'>
  <p class=MsoNormal><u>All survivors at risk:</u><br>
  - Counseling regarding the risk of impaired spermatogenesis and its
  implications for future health and fertility at the request of the survivor
  after informed discussion or when paternity is desired in the forseeable
  future, at least every 5 years<br>
  <br>
  <u>Post-pubertal survivors at risk</u> that desire assessment of potential
  for future fertility:<br>
  - Semen analysis</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:27.5pt'>
  <p class=MsoNormal>Have discussed the possibility to test your semen and get
  to know your fertility status</p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:27.5pt'>
  <p class=MsoNormal><span lang=IT>Semen analysis (if desired)</span></p>
  </td>
  <td style='height:27.5pt;border:none' width=0 height=110></td>
 </tr>
 <tr style='height:20.8pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:20.8pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T5.GUIDELINE_T5</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:20.8pt'>
  <p class=MsoNormal>Male fertility problems and sexual dysfunction<br>
  Testosterone deficiency</p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:20.8pt'>
  <p class=MsoNormal><u>All survivors at risk:</u><br>
  - Counseling regarding the risk of impaired  testosterone deficiency and its
  implications for future health and fertility at the request of the survivor
  after informed discussion or when paternity is desired in the forseeable
  future, at least every 5 years<br>
  <u><br>
  Pre- and peri-pubertal survivors at risk:</u><br>
  - Growth (height) and pubertal development and progression (Tanner stage) at
  least every year, with increasing frequency as clinically indicated depending
  on growth and pubertal progress<br>
  <br>
  Note: Regular growth and pubertal monitoring should be started by no later
  than 12 years (and no earlier than 10 years) of age.<br>
  <br>
  <u>Post-pubertal survivors at risk:</u><br>
  - Early morning testosterone at clinically appropriate time intervals<br>
  - LH in addition to (early morning) testosterone if clinical signs of
  hypogonadism, previous low or borderline testosterone concentrations, or if
  an early morning testosterone sample cannot be obtained, at least every 2-3
  years</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:20.8pt'>
  <p class=MsoNormal>Monitoring of your growth and pubertal development at
  least every year <u>i</u>n currently pre-pubertal and peri-pubertal male
  survivors.</p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal>Blood tests every [] years and have discussed the
  possibility to test your semen and get to know your fertility status in
  currently post-pubertal male survivors  </p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:20.8pt'>
  <p class=MsoNormal>Growth and Tanner stage at least 1x/year (more often if
  clinically indicated)</p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal>Semen analysis (if desire)<br>
  - Early morning testosterone at clinically appropriate intervals <br>
  - LH 1x/2-3 years (if clinically indicated or early morning testosterone not
  possible)</p>
  </td>
  <td style='height:20.8pt;border:none' width=0 height=83></td>
 </tr>
 <tr style='height:105.0pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T6.GUIDELINE_T6</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal>Male fertility problems and sexual dysfunction<br>
  Physical sexual dysfunction</p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal>All survivors at risk:<br>
  - Counseling regarding the risk of physical sexual dysfunction (including
  erectile and ejaculatory dysfunction), and its implications for future health
  and fertility at the request of the survivor after informed discussion or
  when paternity is desired in the forseeable future, at least every 5 years<br>
  <br>
  Post-pubertal survivors at risk<br>
  - Sexual history every 5 years</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal>Not included (see impaired fertility)</p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal>Not included (see impaired fertility)</p>
  </td>
  <td style='height:105.0pt;border:none' width=0 height=420></td>
 </tr>
 <tr style='height:64.5pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:64.5pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T7<br>
  .GUIDELINE_T7</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:64.5pt'>
  <p class=MsoNormal>Premature ovarian insufficiency<br>
  Impaired fertility Amenorrhea<br>
  Premature menopause</p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:64.5pt'>
  <p class=MsoNormal>All survivors at risk: <br>
  - Counselling regarding the risk of premature ovarian insufficiency and its
  implications for future fertility, at least every 5 years<br>
  - Not recommended: measurement of AMH as primary surveillance modality<br>
  <u>Pre- and peri-pubertal survivors at risk:</u><br>
  - Monitoring of growth (height) and pubertal development and progression
  (Tanner stage) at least every year, with increasing frequency as clinically
  indicated based on growth and pubertal progression<br>
  - FSH and oestradiolt in case of failure to initiate or progress through
  puberty at least for girls &#8805; 11 years of age, and for girls with
  primary amenorrhoea (16 years of age)<br>
  <u>Post-pubertal survivors at risk:</u><br>
  - History and physical examination with specific attention to premature
  ovarian insufficiency symptoms (amenorrhoea, irregular cycles) every 5 years<br>
  - FSH and oestradiolt,u in case of menstrual cycle dysfunction suggesting
  premature ovarian insufficiency, or if assessment of potential for future
  fertility is desired</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:64.5pt'>
  <p class=MsoNormal>Monitoring of your growth and pubertal development every
  year <u>in currently pre-pubertal or peri-pubertal female survivors </u></p>
  <p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>
  <p class=MsoNormal>Monitoring of related symptoms and your menstrual cycle
  every 5 years <u>in currently post-pubertal female survivors</u></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:64.5pt'>
  <p class=MsoNormal>Growth and Tanner stage 1x/year (more often if clinically
  indicated) - FSH and oestradiol (if clinically indicated)</p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal>Menstrual cycle 1x/5 years<br>
  - FSH and oestradiol (if clinically indicated)</p>
  </td>
  <td style='height:64.5pt;border:none' width=0 height=258></td>
 </tr>
 <tr style='height:150.65pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:150.65pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T8.GUIDELINE_T8</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:150.65pt'>
  <p class=MsoNormal>Ear problems<br>
  Hearing loss</p>
  <p class=MsoNormal>Tinnitus<br>
  <br>
  </p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:150.65pt'>
  <p class=MsoNormal><u>Survivors &lt; 6 years of age at risk:</u><br>
  - Extensive testing by audiologist every year, to begin no later than the end
  of treatment<br>
  <br>
  <u>Survivors &#8805; 6 years of age at risk</u><br>
  - Pure tone conventional audiometry testing at 1000-8000 Hz<br>
  - Additional testing with high frequency audiometry &gt; 8000 Hz (whenever
  equipment is available), to begin no later than the end of treatment<br>
  - every other year if 6-12 years of age<br>
  - every 5 years for adolescents and young adults &#8805; 12 years of age</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:150.65pt'>
  <p class=MsoNormal>not included under 12 Y</p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal>A hearing test every 5 years in survivors currently 12
  years or older</p>
  </td>
  <td width="24%" nowrap valign=top style='width:24.8%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:150.65pt'>
  <p class=MsoNormal>&nbsp;Audiometry 1000-8000 Hz 1x/5 years <br>
  - Audiometry &gt; 8000 Hz 1x/5 years (if available)<br>
  <br>
  Note: initiate surveillance no later than end of treatment.</p>
  </td>
  <td style='height:150.65pt;border:none' width=0 height=603></td>
 </tr>
 <tr style='height:50.85pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:50.85pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T9.GUIDELINE_T9</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:50.85pt'>
  <p class=MsoNormal>Impaired glucose metabolism and diabetes melitus</p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:50.85pt'>
  <p class=MsoNormal>- Fasting blood glucose with or without HbA1c at least
  every 5 years</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:50.85pt'>
  <p class=MsoNormal>A blood glucose test at least every 5 years</p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:50.85pt'>
  <p class=MsoNormal>Fasting blood glucose with or without HbA1c at least 1x/5
  years</p>
  </td>
  <td style='height:50.85pt;border:none' width=0 height=203></td>
 </tr>
 <tr style='height:47.25pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:47.25pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T10.GUIDELINE_T10</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:47.25pt'>
  <p class=MsoNormal><span lang=IT>Dyslipidemia</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:47.25pt'>
  <p class=MsoNormal>- Fasting lipid profile starting no later than at the age
  of 40 years, and at least every 5 years subsequently<sup>q</sup></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:47.25pt'>
  <p class=MsoNormal>A blood lipid profile at least every 5 years</p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:47.25pt'>
  <p class=MsoNormal>Fasting lipid profile at least 1x/5 years</p>
  </td>
  <td style='height:47.25pt;border:none' width=0 height=189></td>
 </tr>
 <tr style='height:64.55pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:64.55pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T11.GUIDELINE_T11</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:64.55pt'>
  <p class=MsoNormal><span lang=IT>Overweight and obesity</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:64.55pt'>
  <p class=MsoNormal> - Height, weight and BMI at least every 2 years and at
  every LTFU visit</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:64.55pt'>
  <p class=MsoNormal>A height and weight measurement at least every 2 years</p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:64.55pt'>
  <p class=MsoNormal>Height, weight, BMI at least 1x/2 years</p>
  </td>
  <td style='height:64.55pt;border:none' width=0 height=258></td>
 </tr>
 <tr style='height:63.25pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:63.25pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T12.GUIDELINE_T12</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:63.25pt'>
  <p class=MsoNormal><span lang=IT>Hypertension</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:63.25pt'>
  <p class=MsoNormal>- Blood pressure measurement at least every 2 years and at
  every LTFU visit</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:63.25pt'>
  <p class=MsoNormal>A blood pressure measurement at least every 2 years and at
  every long-term follow-up visit</p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:63.25pt'>
  <p class=MsoNormal>Blood pressure at least 1x/2 years and at every LTFU visit</p>
  </td>
  <td style='height:63.25pt;border:none' width=0 height=253></td>
 </tr>
 <tr style='height:169.25pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:169.25pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T13.GUIDELINE_T13</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:169.25pt'>
  <p class=MsoNormal><span lang=IT>Reduced bone mineral density</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:169.25pt'>
  <p class=MsoNormal> A history with specific attention to risk factors (poor
  vitamin D and/or calcium intake, minimal weight-bearing exercise,
  comorbidities) and symptoms (back pain, fractures) of reduced bone mineral
  density at least every 5 years<br>
  - DXA scan once, if possible, and thereafter as clinically indicated<br>
  <br>
  Note: It might be considered to postpone the DXA-scan in pre-pubertal and
  pubertal survivors.<br>
  <br>
  Other advice to be given:<br>
  - Recommend adequate calcium and vitamin D intake, and adequate physical
  activity according to guidelines for the general population</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:169.25pt'>
  <p class=MsoNormal><span lang=IT>A DXA scan once</span></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:169.25pt'>
  <p class=MsoNormal>DXA scan 1x at entry LTFU</p>
  </td>
  <td style='height:169.25pt;border:none' width=0 height=677></td>
 </tr>
 <tr style='height:62.9pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:62.9pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T14.GUIDELINE_T14</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:62.9pt'>
  <p class=MsoNormal><span lang=IT>Osteonecrosis</span></p>
  <p class=MsoNormal><span lang=IT>Avascular necrosis</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:62.9pt'>
  <p class=MsoNormal> - A history for symptoms of osteonecrosis at least every
  5 years. Suspicion of osteonecrosis should always be followed by a timely
  referral to an orthopaedic surgeon</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:62.9pt'>
  <p class=MsoNormal><span lang=IT>Not included</span></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:62.9pt'>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td style='height:62.9pt;border:none' width=0 height=252></td>
 </tr>
 <tr style='height:113.15pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:113.15pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T15<br>
  .GUIDELINE_T15</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:113.15pt'>
  <p class=MsoNormal>Hypothalamic-pituitary (HP) axis problems (High risk)<br>
  Growth hormone deficiency (GHD)<br>
  TSH deficiency (TSHD)<br>
  LH/FSH deficiency (LH/FSHD)<br>
  ACTH deficiency (ACTHD)</p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:113.15pt'>
  <p class=MsoNormal>refer directly to (paediatric) endocrinologist or see in
  multidisciplinary team)</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:113.15pt'>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:113.15pt'>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td style='height:113.15pt;border:none' width=0 height=453></td>
 </tr>
 <tr style='height:70.0pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:70.0pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T16<br>
  .GUIDELINE_T16</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:70.0pt'>
  <p class=MsoNormal>Hypothalamic-pituitary (HP) axis problems (Standard risk)<br>
  Growth hormone deficiency (GHD)<br>
  TSH deficiency (TSHD)<br>
  LH/FSH deficiency (LH/FSHD)<br>
  ACTH deficiency (ACTHD)</p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:70.0pt'>
  <p class=MsoNormal>Pre-pubertal and peri-pubertal survivors at risk:<br>
  - Relevant clinical history for HP axis problems<br>
  - Physical examination for symptoms and signs suggestive of HP axis problems<br>
  - Height velocity in relation to parental height <br>
  - Tanner stage (note: boys exposed to gonadotoxic therapy (e.g. alkylating
  agents and radiotherapy to the testes) may have testes small for pubertal
  stage while in puberty)<br>
  every 6 months, starting 6-12 months after completion of radiotherapy or
  directly after hydrocephalus or CSF shunt occurrence<br>
  - fT4, TSH, morning cortisol<br>
  every year, starting 6-12 months completion of radiotherapy or directly after
  hydrocephalus or CSF shunt occurrence<br>
  Post-pubertal survivors at risk:<br>
  - Relevant clinical history for HP axis problems<br>
  - Physical examination for symptoms and signs suggestive of HP axis problems<br>
  - Evaluation of menstrual cycle (females)<br>
  - fT4, TSH, morning cortisol, IGF-1<br>
  - Morning testosterone, or free testosterone if overweight, and LH (males)<br>
  - Estradiol, FSH and LH (females)<br>
  every year, starting 6-12 months from the end of radiotherapy or directly
  after hydrocephalus or CSF shunt occurrence<br>
  <br>
  Note: an IGF-1 level even as high as 0 SDS does not rule out GHD.<br>
  Note: continue surveillance at least 15 years from exposure. Continuation of
  surveillance should be a shared decision between survivor and HCP considering
  available health care resources. If surveillance is terminated, the survivor
  should be educated about possible signs and symptoms of HP axis problems.</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:70.0pt'>
  <p class=MsoNormal>Monitoring of your growth and pubertal development every 6
  months and blood tests every year in currently pre-pubertal and peri-pubertal
  male and female survivors</p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal>Monitoring of your menstrual cycle and blood tests every
  year in currently post-pubertal female survivors</p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal>Blood tests every year  in currently post-pubertal male
  survivors</p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:70.0pt'>
  <p class=MsoNormal>Height velocity, Tanner stage 1x/6 months - <br>
  - fT4, TSH, morning cortisol 1x/year<br>
  <br>
  Note: initiate surveillance at &#8805; 6 months after radiotherapy, even in
  the absence of symptoms. Continue up to 15 years after radiotherapy exposure.
  Afterwards, continuation of surveillance is a shared decision.</p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal>fT4, TSH, morning cortisol, IGF-1 1x/year <br>
  <br>
  Note: initiate surveillance at &#8805; 6 months after diagnosis, even in the
  absence of symptoms. Continue up to 15 years after diagnosis. Afterwards,
  continuation of surveillance is a shared decision.</p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal>fT4, TSH, morning cortisol, IGF-1 1x/year <br>
  Morning testosterone or free testosterone 1x/year (in overweight males)<br>
  <br>
  Note: initiate surveillance at &#8805; 6 months after radiotherapy, even in
  the absence of symptoms. Continue up to 15 years after radiotherapy exposure.
  Afterwards, continuation of surveillance is a shared decision</p>
  </td>
  <td style='height:70.0pt;border:none' width=0 height=280></td>
 </tr>
 <tr style='height:63.0pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:63.0pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T17.GUIDELINE_T17</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:63.0pt'>
  <p class=MsoNormal>Central precocious puberty (CPP)<br>
  For girls with age below 8 years </p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:63.0pt'>
  <p class=MsoNormal>Relevant clinical history for symptoms of central
  precocious puberty<br>
  - Physical examination for signs of central precocious puberty<br>
  - Height velocity in relation to parental height<br>
  - Tanner stage every 6 starting 6-12 months after completion of radiotherapy
  or directly after hydrocephalus or CSF shunt occurrence</p>
  <p class=MsoNormal> Note: Continue surveillance until the age of 8 years for
  girls <br>
  - Refer to a paediatric endocrinologist if there are clinical symptoms and
  signs suggestive for central precocious puberty, or if morning testosterone
  is abnormal<br>
  - Counsel survivors with (a suspicion of) central precocious puberty on
  overall health as well as the risk for short stature associated with
  untreated central precocious puberty, and assist them with coordinating and
  obtaining an early referral when appropriate</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:63.0pt'>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:63.0pt'>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td style='height:63.0pt;border:none' width=0 height=252></td>
 </tr>
 <tr style='height:63.0pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:63.0pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T18.GUIDELINE_T18</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:63.0pt'>
  <p class=MsoNormal>Central precocious puberty (CPP)<br>
  For boys with age below 9 yearss</p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:63.0pt'>
  <p class=MsoNormal>Relevant clinical history for symptoms of central
  precocious puberty<br>
  - Physical examination for signs of central precocious puberty<br>
  - Height velocity in relation to parental height<br>
  - Tanner stage every 6 months, starting 6-12 months after completion of
  radiotherapy or directly after hydrocephalus or CSF shunt occurrence<br>
  - Morning testosterone every year, starting 6-12 months after completion of
  radiotherapy or directly after hydrocephalus or CSF shunt occurrence<br>
  Note: Continue surveillance until the age of  9 years for boys. Boys exposed
  to radiotherapy to the testes may have testes small for pubertal stage while
  in puberty. Instead, morning testosterone (before 10:00 AM) should be used as
  screening modality as testicular volume may be unreliable</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:63.0pt'>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:63.0pt'>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td style='height:63.0pt;border:none' width=0 height=252></td>
 </tr>
 <tr style='height:41.65pt'>
  <td width="10%" rowspan=2 valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:41.65pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T19.GUIDELINE_T19</span></p>
  </td>
  <td width="15%" rowspan=2 valign=top style='width:15.5%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:41.65pt'>
  <p class=MsoNormal>Thyroid function problems<br>
  Hypothyroidism<br>
  Hyperthyroidism</p>
  </td>
  <td width="34%" rowspan=2 valign=top style='width:34.12%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:41.65pt'>
  <p class=MsoNormal> A history with specific attention to hypothyroidism
  and/or hyperthyroidism <br>
  - TSH and fT4 measurement <br>
  - every year in survivors &#8804; 18 years of age<br>
  - at least every 2-3 years in survivors &gt; 18 years of age<br>
  Female survivors at risk of hypothyroidism:<br>
  - Discuss the importance of measuring TSH and fT4 prior to attempting
  pregnancy and periodically during pregnancy at least every 5 years<br>
  - Measure TSH and fT4 prior to attempting pregnancy and periodically during
  pregnancy</p>
  </td>
  <td width="15%" rowspan=2 valign=top style='width:15.5%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:41.65pt'>
  <p class=MsoNormal>Blood tests of your thyroid gland function [every year]
  [at least every 2-3 years] [, before attempting pregnancy and periodically
  during pregnancy]</p>
  </td>
  <td width="24%" rowspan=2 valign=top style='width:24.8%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:41.65pt'>
  <p class=MsoNormal>TSH, fT4 1x/year ( if &#8804; 18 years)- -TSH, fT4 1x/2-3
  years (if &gt; 18 years)</p>
  <p class=MsoNormal>-TSH, fT4 prior to attempting pregnancy and periodically
  during pregnancy (if female)</p>
  </td>
  <td style='height:41.65pt;border:none' width=0 height=167></td>
 </tr>
 <tr style='height:63.0pt'>
  <td style='height:63.0pt;border:none' width=0 height=252></td>
 </tr>
 <tr style='height:70.9pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:70.9pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T20<br>
  .GUIDELINE_T20</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:70.9pt'>
  <p class=MsoNormal>Cerebrovascular problem</p>
  <p class=MsoNormal>Carotid artery disease<br>
  Cerebrovascular accidents<br>
  Aneurysm<br>
  Cavernomas</p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:70.9pt'>
  <p class=MsoNormal> Discuss the importance of controlling cardiovascular and
  stroke risk factors (hypertension, diabetes, dyslipidaemia, obesity, smoking
  and low levels of physical activity)<br>
  - Perform imaging as appropriate and/or refer to a neurologist, neurosurgeon
  or vascular specialist</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:70.9pt'>
  <p class=MsoNormal><span lang=IT>Not included</span></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:70.9pt'>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td style='height:70.9pt;border:none' width=0 height=284></td>
 </tr>
 <tr style='height:161.9pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:161.9pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T21<br>
  .GUIDELINE_T21</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:161.9pt'>
  <p class=MsoNormal>Neurocognitive problems<br>
  Academic and school performance<br>
  Attention<br>
  Executive functions<br>
  Intelligence<br>
  Language<br>
  Memory<br>
  Processing speed<br>
  Visual-motor integration<br>
  Risk especially if the survivor was treated at a young age<br>
  <br>
  </p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:161.9pt'>
  <p class=MsoNormal>A history with specific attention to educational and/or
  vocational progress or decline <br>
  - at least every 2 years in survivors &#8804; 18 years of age<br>
  - at least every 5 years in survivors &gt; 18 years of age<br>
   -  Refer to a (neuro)psychologist for a formal neuropsychological evaluation
  in case of abnormalities</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:161.9pt'>
  <p class=MsoNormal><span lang=IT>Not included</span></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:161.9pt'>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td style='height:161.9pt;border:none' width=0 height=648></td>
 </tr>
 <tr style='height:21.15pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T22.GUIDELINE_T22</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt'>
  <p class=MsoNormal><span lang=IT>Peripheral neuropathy<br>
  Sensory peripheral neuropathy<br>
  Motor peripheral neuropathy</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt'>
  <p class=MsoNormal>Refer to the appropriate HCP<br>
  - Consider medication for painful neuropathy</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt'>
  <p class=MsoNormal><span lang=IT>Not included</span></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt'>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td style='height:21.15pt;border:none' width=0 height=85></td>
 </tr>
 <tr style='height:78.75pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:78.75pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T23<br>
  .GUIDELINE_T23</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:78.75pt'>
  <p class=MsoNormal><span lang=IT>Cataract</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:78.75pt'>
  <p class=MsoNormal>A history with specific attention to symptoms of cataract
  at least every 5 years<br>
  - Refer to an ophthalmologist or ocular specialist in case of abnormalities<br>
    </p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:78.75pt'>
  <p class=MsoNormal><span lang=IT>Not included</span></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:78.75pt'>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td style='height:78.75pt;border:none' width=0 height=315></td>
 </tr>
 <tr style='height:161.1pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:161.1pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T24.GUIDELINE_T24</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:161.1pt'>
  <p class=MsoNormal><span lang=FR>Eye problems<br>
  Lacrimal duct atrophy (risk with radioiodine therapy)<br>
  Xerophtalmia<br>
  Keratitis<br>
  Telangiectasias<br>
  Retinopathy<br>
  Optic chiasm neuropathy<br>
  Chronic painful eye<br>
  Maculopathy<br>
  Papillopathy<br>
  Visual field deficits<br>
  Glaucoma</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:161.1pt'>
  <p class=MsoNormal>A history with specific attention to symptoms of problems
  of the eye and orbit at least every 5 years<br>
  - A physical eye examination for external eye abnormalities at least every 5
  years      - Refer to an ophthalmologist or ocular specialist in case of
  abnormalities</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:161.1pt'>
  <p class=MsoNormal><span lang=IT>Not included</span></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:161.1pt'>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td style='height:161.1pt;border:none' width=0 height=644></td>
 </tr>
 <tr style='height:105.0pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T25.GUIDELINE_T25</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal>Craniofacial growth problems<br>
  Craniofacial growth disturbance<br>
  Orbital hypoplasia<br>
  Psychological adjustment difficulties due to craniofacial growth problems</p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal>A physical examination for craniofacial growth problems at
  least every 5 years<br>
  Refer to a reconstructive craniofacial surgeon if craniofacial growth
  problems are identified<br>
  - Perform a psychosocial history with specific attention to adjustment
  difficulties and refer to a psychologist if clinically indicated</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal><span lang=IT>Not included</span></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td style='height:105.0pt;border:none' width=0 height=420></td>
 </tr>
 <tr style='height:42.0pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:42.0pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T26.GUIDELINE_T26</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:42.0pt'>
  <p class=MsoNormal>Spine scoliosis and kyphosis<br>
  Spine scoliosis<br>
  Spine kyphosis</p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:42.0pt'>
  <p class=MsoNormal> A physical examination of the spine every year until
  growth is completed; the surveillance frequency may be increased during
  puberty. - Perform imaging and/or refer to an orthopaedic surgeon or physical
  therapist as clinically indicated in case of abnormalities</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:42.0pt'>
  <p class=MsoNormal><span lang=IT>Not included</span></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:42.0pt'>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td style='height:42.0pt;border:none' width=0 height=168></td>
 </tr>
 <tr style='height:63.0pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:63.0pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T27.GUIDELINE_T27</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:63.0pt'>
  <p class=MsoNormal>Lower urinary tract problems<br>
  Hemorrhagic cystitis<br>
  Bladder fibrosis<br>
  Dysfunctional voiding<br>
  Vesicoureteral reflux<br>
  Neurogenic bladder <br>
  Hydronephrosis</p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:63.0pt'>
  <p class=MsoNormal> A history with specific attention to urinary tract
  symptoms at least every 5 years. Perform a urinalysis including cytology and
  urine culture<br>
  - Refer to a urologist if the urinalysis results are abnormal</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:63.0pt'>
  <p class=MsoNormal><span lang=IT>Not included</span></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:63.0pt'>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td style='height:63.0pt;border:none' width=0 height=252></td>
 </tr>
 <tr style='height:70.0pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:70.0pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T28.GUIDELINE_T28</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:70.0pt'>
  <p class=MsoNormal>Obstetric problems <br>
  Miscarriage<br>
  Premature birth Low birth weight</p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:70.0pt'>
  <p class=MsoNormal> All female survivors at risk of reproductive age:<br>
  - Discuss the risk of adverse obstetric outcomes (miscarriage, premature
  birth, low birth weight; but not congenital anomalies)<br>
  - High-risk obstetric surveillance during pregnancy</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:70.0pt'>
  <p class=MsoNormal><span lang=IT>Not included</span></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:70.0pt'>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td style='height:70.0pt;border:none' width=0 height=280></td>
 </tr>
 <tr style='height:105.0pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T29.GUIDELINE_T29</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal>Dental and oral problems<br>
  Dental caries<br>
  Dental developmental problems (especially if treated at a young age or having
  experienced a poor nutritional condition)<br>
  Xerostomia<br>
  Periodontal disease</p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal>Refer to specialist dental care or orthodontist if there
  are significant dental problems related to previous treatment</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal><span lang=IT>Not included</span></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td style='height:105.0pt;border:none' width=0 height=420></td>
 </tr>
 <tr style='height:105.0pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T30.GUIDELINE_T30</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal>Gastro-intestinal problems<br>
  Bowel stenosis or obstruction<br>
  Cholelithiasis<br>
  Chronic enterocolitis<br>
  Faecal incontinence<br>
  Gastro-intestinal fistula<br>
  Malabsorption<br>
  Oesophageal stenosis or sticture<br>
  Neurogenic bowel</p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal> Perform appropriate diagnostic tests and/or Refer to A
  surgeon or gastro-enterologist </p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal><span lang=IT>Not included</span></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td style='height:105.0pt;border:none' width=0 height=420></td>
 </tr>
 <tr style='height:189.0pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:189.0pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T32<br>
  .GUIDELINE_T32</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:189.0pt'>
  <p class=MsoNormal><span lang=IT>Pulmonary problems<br>
  Pulmonary dysfunction</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:189.0pt'>
  <p class=MsoNormal>History with specific attention to pulmonary dysfunction
  at least every 5 years<br>
  - Physical pulmonary examination at least every 5 years<br>
  - Pulmonary function tests, including spirometry and diffusing capacity for
  carbon monoxide (DLCO), once at entry into LTFU <br>
  - Consider pneumococcal vaccination status according to local or national
  guidelines<br>
  <br>
  Other advice:<br>
  - Avoid tobacco, quit smoking and/or reduce exposure to environmental smoke<br>
  If initial pulmonary function test is abnormal:<br>
  - Consult with or refer to pulmonologist<br>
  <br>
  If any abnormalities are identified during subsequent follow-up visits<br>
  - Repeat pulmonary function tests<br>
  - Consult with or refer to pulmonologist if they are abnormal</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:189.0pt'>
  <p class=MsoNormal> Lung tests once, get a yearly influenza vaccination and
  avoid smoking                              - Pulmonary function tests
  including spirometry and DLCO 1x at entry LTFU<br>
  - Influenza vaccination 1x/year<br>
  - Check pneumococcal vaccination status according to local or national
  guidelines</p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:189.0pt'>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td style='height:189.0pt;border:none' width=0 height=756></td>
 </tr>
 <tr style='height:105.0pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T33.GUIDELINE_T33</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal>Renal problems<br>
  Glomerular dysfunction<br>
  Tubular dysfunction</p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal>Glomerular function testing including blood testing
  (creatinine), urine testing (creatinine, proteinuria), eGFR calculation, at
  least every 5 years<br>
  - Additional tubular function testing including blood testing (Na, K, Mg, P,
  Ca, phosphate, albumin) and urine testing (glucose, phosphate) at least every
  5 years<br>
  Other advice:<br>
  - Education about caution in the use of NSAIDs<br>
  - Counselling about single kidney-related health risks<br>
  - Electrolyte supplementation as guided by serum biochemistry if an
  electrolyte imbalance is detected<br>
  - Refer to nephrologist if proteinuria and/or chronic kidney disease are
  identified</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal>Blood and urine tests of the kidney at least every 5
  years:    </p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:105.0pt'>
  <p class=MsoNormal> - Urine creatinine, proteinuria, glucose, P at least 1x/5
  years<br>
  - eGFR at least 1x/5 years</p>
  </td>
  <td style='height:105.0pt;border:none' width=0 height=420></td>
 </tr>
 <tr style='height:91.25pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:91.25pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T47.GUIDELINE_T47</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:91.25pt'>
  <p class=MsoNormal><span lang=IT>Renal problems<br>
  Tubular dysfunction</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:91.25pt'>
  <p class=MsoNormal>Glomerular function testing including blood testing
  (creatinine), urine testing (creatinine, proteinuria), eGFR calculation, at
  least every 5 years</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:91.25pt'>
  <p class=MsoNormal>Blood and urine tests of the kidney at least every 5
  years   </p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:91.25pt'>
  <p class=MsoNormal> - Blood creatinine at least 1x/5 years<br>
  - Urine creatinine, proteinuria at least 1x/5 years<br>
  - eGFR at least 1x/5 years</p>
  </td>
  <td style='height:91.25pt;border:none' width=0 height=365></td>
 </tr>
 <tr style='height:63.0pt'>
  <td width="10%" rowspan=2 valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:63.0pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T34<br>
  .GUIDELINE_T34</span></p>
  </td>
  <td width="15%" rowspan=2 valign=top style='width:15.5%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:63.0pt'>
  <p class=MsoNormal>Liver problems <br>
  Liver fibrosis or cirrhosis<br>
  Hepatocellular liver injury <br>
  Hepatobiliary dysfunction <br>
  Biliary tract injury <br>
  Liver synthetic dysfunction</p>
  </td>
  <td width="34%" rowspan=2 valign=top style='width:34.12%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:63.0pt'>
  <p class=MsoNormal> Physical examination for height, weight, BMI and signs of
  liver disease or bile duct injury (i.e. hepatosplenomegaly, spider naevi or
  pruritus) <br>
  - Serum liver enzyme concentrations (ALT, AST, gGT, ALP) once at entry into
  LTFU<br>
  - Physical examination for height, weight, BMI and signs of liver disease or
  bile duct injury (i.e. hepatosplenomegaly, spider naevi or pruritus) <br>
  - Serum liver enzyme concentrations (ALT, AST, gGT, ALP)<br>
  once at entry into LTFU<br>
   In case of increased liver enzyme values:<br>
  - Between 1-2 x ULN: repeat the test within 1 year.<br>
  - &gt; 2x ULN: repeat the test within 2 months.<br>
  In case of persistent liver abnormalities (&gt; ULN):<br>
  - Refer to a hepatologist or gastroenterologist for further examination if
  there is no obvious explanation (alcohol, medication, obesity)<br>
  - Avoid or prescribe with caution potentially hepatotoxic medications and
  supplements<br>
  - Evaluate body mass index and discuss healthy weight goals, especially in
  those with evidence of metabolic syndrome<br>
  - Consider immunization against hepatitis A and B if not already immune<br>
  - Counsel about importance of measures to maintain liver health:<br>
  Cautious use or avoidance of alcohol intake<br>
  Maintain a healthy weight and lifestyle<br>
  Precautions to reduce viral transmission to household and sexual contacts in
  survivors with chronic HBV/HCV infection</p>
  </td>
  <td width="15%" rowspan=2 valign=top style='width:15.5%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:63.0pt'>
  <p class=MsoNormal>Blood tests of the liver once</p>
  </td>
  <td width="24%" rowspan=2 valign=top style='width:24.8%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:63.0pt'>
  <p class=MsoNormal>ALT, AST, gGT, ALP 1x at entry LTFU.</p>
  <p class=MsoNormal>In case of chronic viral hepatitis: - Follow-up by an
  appropriate specialist (e.g. hepatologist or infectious diseases specialist)
  according to the local or national hepatitis clinical practice guidelines. </p>
  </td>
  <td style='height:63.0pt;border:none' width=0 height=252></td>
 </tr>
 <tr style='height:78.75pt'>
  <td style='height:78.75pt;border:none' width=0 height=315></td>
 </tr>
 <tr style='height:78.75pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:78.75pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T35<br>
  .GUIDELINE_T35</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:78.75pt'>
  <p class=MsoNormal><span lang=IT>Iron overload </span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:78.75pt'>
  <p class=MsoNormal>Serum ferritin, once at entry into LTFU In case of
  increased serum ferritin (&gt;500 ng/ml):<br>
  - Repeat test within 6 months<br>
  <br>
  If persistent abnormal serum ferritin levels (&gt;500 ng/ml):<br>
  - Perform a MRI T2* to quantify the liver iron content<br>
  <br>
  If confirmed elevated liver iron content:<br>
  - Refer to a hematologist or other specialist to start treatment, such as
  phlebotomy or chelation therapy</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:78.75pt'>
  <p class=MsoNormal>Blood tests of iron levels once</p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:78.75pt'>
  <p class=MsoNormal>- Serum ferritin 1x at entry LTFU</p>
  </td>
  <td style='height:78.75pt;border:none' width=0 height=315></td>
 </tr>
 <tr style='height:21.15pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T36<br>
  .GUIDELINE_T36</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt'>
  <p class=MsoNormal><span lang=IT>Spleen problems</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt'>
  <p class=MsoNormal> Educate about events that necessitate immediate start of
  therapeutic antibiotics and prompt evaluation by a HCPb<br>
  - Ensure that therapeutic antibiotics are readily available<br>
  - Advise wearing medical bracelet or carrying patient card<br>
  - Discuss importance of seeking expert advice when travelling to endemic
  areas.       In case of fever &gt; 38.3 °C,  infective or septic symptoms, or
  animal or human bite with skin break:<br>
  - Arrange prompt evaluation by a HCP including a physical examination, blood
  count and blood culture<br>
  - Immediately treat with therapeutic antibiotics according to local and
  national policies until blood culture results are available</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt'>
  <p class=MsoNormal>Access to immediate medical help when you:<br>
   have a fever of &gt; 38.3 °C (even if you do not have any other symptoms)<br>
    feel ill<br>
   have been bitten by a person or animal with skin break. <br>
  You might need antibiotics very soon after any of these events.<br>
  <br>
  If you consider travelling to areas where malaria or other infectious
  diseases are endemic, it is recommended to seek advice from experts at the
  long-term follow-up clinic or at the travel clinic. They can advise you on
  the travel vaccines and anti-malarial medications that you might need.<br>
  <br>
  </p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt'>
  <p class=MsoNormal>Counsel about spleen-related risks and precautions <br>
  - Perform a blood count, blood culture and immediately treat with therapeutic
  antibiotics until blood culture results are available, in case of fever &gt;
  38.3 °C, illness or a bite mark with skin break</p>
  </td>
  <td style='height:21.15pt;border:none' width=0 height=85></td>
 </tr>
 <tr style='height:70.7pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:70.7pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T37.GUIDELINE_T37</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:70.7pt'>
  <p class=MsoNormal><span lang=IT>Tumor predisposition</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:70.7pt'>
  <p class=MsoNormal>Surveillance strategy in survivors with, or with a
  suspicion of, a hereditary cancer syndromem:<br>
  - Additional consultation by a clinical geneticist to determine
  individualised surveillance methods and frequency at entry into LTFU</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:70.7pt'>
  <p class=MsoNormal><span lang=IT>Not included</span></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:70.7pt'>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td style='height:70.7pt;border:none' width=0 height=283></td>
 </tr>
 <tr style='height:97.95pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:97.95pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T38.GUIDELINE_T38</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:97.95pt'>
  <p class=MsoNormal><span lang=IT>Subsequent melanoma and non-melanoma skin
  cancer<br>
  Basal cell carcinoma<br>
  Squamous cell carcinoma<br>
  Melanoma</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:97.95pt'>
  <p class=MsoNormal>Self-examination for new spots and changing moles, at
  least every 6 months<br>
  - History at least every 2 years<br>
  - Skin examination at least every 2 years - Refer to a dermatologist in case
  of abnormalities</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:97.95pt'>
  <p class=MsoNormal><span lang=IT>Not included</span></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:97.95pt'>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td style='height:97.95pt;border:none' width=0 height=392></td>
 </tr>
 <tr style='height:91.7pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:91.7pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T39.GUIDELINE_T39</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:91.7pt'>
  <p class=MsoNormal><span lang=IT>Subsequent colorectal cancer</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:91.7pt'>
  <p class=MsoNormal>FOBT every 3 years <br>
  - As an alternative surveillance method, colonoscopy might be considered
  every 5 years<br>
   starting 5 years after radiation or at the age of 30 years, whichever occurs
  last - Positive FOBT should always be followed by a timely colonoscopy</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:91.7pt'>
  <p class=MsoNormal>[A stool sample test for hidden blood (FOBT) every 3
  years] [a colonoscopy every 5 years]</p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:91.7pt'>
  <p class=MsoNormal>FOBT 1x/3 years<br>
  OR<br>
  - Colonoscopy 1x/5 years<br>
  <br>
  Note: start 5 years after radiation or at the age of 30 years, whichever
  occurs last</p>
  </td>
  <td style='height:91.7pt;border:none' width=0 height=367></td>
 </tr>
 <tr style='height:190.5pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:190.5pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T40.GUIDELINE_T40</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:190.5pt'>
  <p class=MsoNormal><span lang=IT>Subsequent Oral Cancer</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:190.5pt'>
  <p class=MsoNormal>Discuss the importance of prompt reporting of new symptoms
  or masses<br>
  - Discuss healthy lifestyle ecommendations<br>
  - Encourage reduction of risk behaviour (smoking, alcohol consumption, drug
  use, sun exposure)<br>
  - Encourage HPV vaccination (according to national guidelines) and consider
  advising safe sexual practices<br>
  - Encourage participation in the national cancer screening programmes, unless
  more intensive or earlier surveillance is specified in the guidelinesl<br>
  Surveillance strategy in all survivors:<br>
  - Family history of malignancies, at least every 5 years.<br>
  In survivors with, or with a suspicion of, a hereditary cancer syndromem:<br>
  - Additional consultation by a clinical geneticist to determine
  individualised surveillance methods and frequency at entry into LTFU</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:190.5pt'>
  <p class=MsoNormal><span lang=IT>Not included</span></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:190.5pt'>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td style='height:190.5pt;border:none' width=0 height=762></td>
 </tr>
 <tr style='height:197.55pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:197.55pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T42.GUIDELINE_T42</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:197.55pt'>
  <p class=MsoNormal><span lang=IT>Subsequent bladder cancer</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:197.55pt'>
  <p class=MsoNormal>General advice:<br>
  - Discuss the importance of prompt reporting of new symptoms or masses<br>
  - Discuss healthy lifestyle recommendations<br>
  - Encourage reduction of risk behaviour (smoking, alcohol consumption, drug
  use, sun exposure)<br>
  - Encourage participation in the national cancer screening programmes, unless
  more intensive or earlier surveillance is specified in the guidelinesl<br>
  <br>
  Surveillance strategy in all survivors:<br>
  - Family history of malignancies, at least every 5 years<br>
  <br>
  Surveillance strategy in survivors with, or with a suspicion of, a hereditary
  cancer syndromem:<br>
  - Additional consultation by a clinical geneticist to determine
  individualised surveillance methods and frequency at entry into LTFU</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:197.55pt'>
  <p class=MsoNormal><span lang=IT>Not included</span></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:197.55pt'>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td style='height:197.55pt;border:none' width=0 height=790></td>
 </tr>
 <tr style='height:247.2pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:247.2pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T43.GUIDELINE_T43</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:247.2pt'>
  <p class=MsoNormal><span lang=IT>Subsequent Bone Cancer</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:247.2pt'>
  <p class=MsoNormal>General advice:<br>
  - Discuss the importance of prompt reporting of new symptoms or masses<br>
  - Discuss healthy lifestyle recommendations<br>
  - Encourage reduction of risk behaviour (smoking, alcohol consumption, drug
  use, sun exposure)<br>
  - Encourage HPV vaccination (according to national guidelines) and consider
  advising safe sexual practices<br>
  - Encourage participation in the national cancer screening programmes, unless
  more intensive or earlier surveillance is specified in the guidelinesl<br>
  <br>
  Surveillance strategy in all survivors:<br>
  - Family history of malignancies, at least every 5 years<br>
  <br>
  Surveillance strategy in survivors with, or with a suspicion of, a hereditary
  cancer syndromem:<br>
  - Additional consultation by a clinical geneticist to determine
  individualised surveillance methods and frequency at entry into LTFU</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:247.2pt'>
  <p class=MsoNormal><span lang=IT>Not included</span></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:247.2pt'>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td style='height:247.2pt;border:none' width=0 height=989></td>
 </tr>
 <tr style='height:183.4pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:183.4pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T44.GUIDELINE_T44</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:183.4pt'>
  <p class=MsoNormal><span lang=IT>Subsequent lung cancer</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:183.4pt'>
  <p class=MsoNormal>General advice:<br>
  - Discuss the importance of prompt reporting of new symptoms or masses<br>
  - Discuss healthy lifestyle recommendations<br>
  - Encourage reduction of risk behaviour (smoking, alcohol consumption, drug
  use, sun exposure)<br>
  - Encourage participation in the national cancer screening programmes, unless
  more intensive or earlier surveillance is specified in the guidelinesl<br>
  Surveillance strategy in all survivors:<br>
  - Family history of malignancies, at least every 5 years<br>
  Surveillance strategy in survivors with, or with a suspicion of, a hereditary
  cancer syndromem:<br>
  - Additional consultation by a clinical geneticist to determine
  individualised surveillance methods and frequency at entry into LTFU</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:183.4pt'>
  <p class=MsoNormal><span lang=IT>Not included</span></p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:183.4pt'>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td style='height:183.4pt;border:none' width=0 height=734></td>
 </tr>
 <tr style='height:84.15pt'>
  <td width="10%" valign=top style='width:10.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:84.15pt'>
  <p class=MsoNormal><span lang=FR>passport_n.GUIDELINE_T45.GUIDELINE_T45</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:84.15pt'>
  <p class=MsoNormal><span lang=FR>Subsequent CNS neoplasms <br>
  Meningiomas<br>
  (High-grade) gliomas<br>
  Other CNS neoplasms (Pituitary tumors, neurilemmoma/schwannoma, opticus
  glioma, craniopharyngioma, medulloblastoma, pineal tumors, pilocytic
  astrocytoma, choroid plexus tumors, ependymoma, supratentorial tumor,
  oligodendroglioma, ganglioglioma)</span></p>
  </td>
  <td width="34%" valign=top style='width:34.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:84.15pt'>
  <p class=MsoNormal>Inform about symptoms and sign that may be related to a
  subsequent CNS neoplasm<br>
  - Neurologic history at every LTFU visit, which may be at 1-5 year intervals<br>
  - Neurologic examination at every LTFU visit, which may be at 1-5 year
  intervals<br>
  Note: No recommendation can be formulated for routine MRI surveillance for
  asymptomatic survivors. The decision to undertake MRI surveillance should be
  made by the CAYA cancer survivor and HCP after careful consideration of the
  potential harms and benefits of MRI surveillance.</p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:84.15pt'>
  <p class=MsoNormal>Discussed the advantages and disadvantages of regular MRIs
  with your doctor</p>
  </td>
  <td width="24%" valign=top style='width:24.8%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:84.15pt'>
  <p class=MsoNormal>Discuss potential harms and benefits of MRI surveillance</p>
  </td>
  <td style='height:84.15pt;border:none' width=0 height=337></td>
 </tr>
</table>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

</div>

</body>

</html>
